secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001214659-24-020439
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro reports Q2 fiscal 2025: cash $4.1M, equity $3.8M, five Phase II trials planned in 2025
--------------------------------------------------------------------------------

- Net cash from financing $8.3M for six months ended Oct 31, 2024; stockholder equity improved to $3.8M from a $2.6M deficit.
- Cash increased to $4.1M from $0.4M; total liabilities reduced to $1.3M from $3.2M at April 30, 2024.
- Regained Nasdaq compliance; entered $25M preferred stock/warrant agreement and $6.5M ATM facility.
- AL001 (lithium cocrystal) to initiate five Phase II trials in 2025 with Mass General for Alzheimer's, BD, MDD, PTSD.
- ALZN002 immunotherapy trial resumption planned for 2025 after re-engaging a new CRO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924020439/0001214659-24-020439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924020439/d12122438k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-020439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer